A recent Eli Lilly study found patients on Mounjaro were 38% less likely to be hospitalized and showed improved heart failure symptoms.
The phase 3 clinical trial evaluating use of tirzepatide — the drug's generic name — injection (5 mg, 10 mg or 15 mg) in adults with heart failure with preserved ejection fraction and obesity. The trial lasted for 52 weeks.
The study found patients on Mounjaro injections were less likely to be hospitalized, less likely to increase their heart failure medication or die of heart complications, and had fewer symptoms such as shortness of breath, fatigue, and swelling of the lower legs, according to an Aug. 1 company news release.
The results have not been peer reviewed.